{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:17:34Z","timestamp":1794129454627,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jacc.2021.11.055","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T15:30:53Z","timestamp":1644852653000},"page":"617-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk"],"prefix":"10.1016","volume":"79","author":[{"given":"Mark","family":"Trinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaavya","family":"Paruchuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Haidermota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Maryam","family":"Zekavat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gilliland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.11.055_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: lipoprotein(a) diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib2","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2021.11.055_bib4","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41467-018-04668-w","article-title":"Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries","volume":"9","author":"Zekavat","year":"2018","journal-title":"Nat Comm"},{"key":"10.1016\/j.jacc.2021.11.055_bib5","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.11.055_bib6","first-page":"78","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.11.055_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib8","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.055_bib9","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.055_bib10","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.055_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.055_bib12","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Articles Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.055_bib13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.055_bib14","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib16","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib18","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.055_bib19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.055_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a) Rx and IONIS-APO(a)-L Rx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2021.11.055_bib21","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.055_bib22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.055_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2021.11.055_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1194\/jlr.P066258","article-title":"Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: The EPIC-Norfolk Prospective Population study","volume":"57","author":"Verbeek","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.11.055_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.11.055_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.055_bib27","author":"Therneau"},{"key":"10.1016\/j.jacc.2021.11.055_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114397","article-title":"Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.11.055_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2020","journal-title":"Arterioscler Thromb Vasc"},{"key":"10.1016\/j.jacc.2021.11.055_bib30","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.11.055_bib32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.11.055_bib33","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2021.11.055_bib34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50\u00a0mg\/dL (105\u00a0nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.11.055_bib36","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.055_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.055_bib39","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.055_bib40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2022.06.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721083935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721083935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T10:47:09Z","timestamp":1726656429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721083935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0735109721083935"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.055","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}